ISG15 and neoplasm: Based on these data, we speculate that ISG15 recruit T lymphocytes on one hand, and on the other hand, since ISG15 can decrease PD-L1 in tumor cells, thus allowing these T cells with antitumor effects to enter the tumor microenvironment without inhibiting their activity and exerting antitumor immunity.